Furthermore, a significant correlation was observed (p < 0.001) between FABP4 and UCP2 expression in CRC tissue specimens (Fig. 3E), highlighting the crucial role of the FABP4/UCP2 axis in regulating clinical responses to cetuximab treatment. Here, UCP2 is linked to colorectal carcinoma.